April 15, 2021 -- Alligator Bioscience has entered a joint research collaboration with MacroGenics focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer.
The collaboration will leverage Alligator's proprietary patient specific immunotherapy Neo-X-Prime and incorporate MacroGenics' proprietary Dart and Trident multispecific platforms against two undisclosed targets. Neo-X-Prime is used for the development of personalized immunotherapy and physically links circulating tumor material to the immune system to allow neoantigen-specific T-cell priming. The Dart and Trident platforms enable the creation of bispecific molecules (those that simultaneously bind two targets).
Under the joint research collaboration, including activities leading up to investigational new drug application-enabling studies, each company will be responsible for its own costs. The companies may continue further development of the resulting bispecific molecule under a separate co-development collaboration and licensing agreement.
Copyright © 2021 scienceboard.net